Peptide Atlas · Peptide

Survodutide

Survodutide is a dual glucagon and GLP-1 receptor agonist; in a 48-week phase 2 trial in 293 adults with biopsy-confirmed MASH and fibrosis, MASH improved without fibrosis worsening in 43% to 62% on survodutide against 14% on placebo.

emerging

provisional
PubChem 171378821
1 citation
0 discussions
0 followers
BI 456906

Follow this molecule Ask the Hunter-Gatherer

What the evidence says

six tiers, never blended

emerging — human data exists, and it is thin or contested

every claim resolves to its source

All 1 citation resolves to their original source. · 0 posts naming it, 0 members counted once each.

No open questions on file. Either everything about this molecule is known, or nobody has admitted what is not.

Negative findings

failure is information

Nobody has filed a failure yet. Failures are information; this list is waiting for an honest one.